Talon Therapeutics

Talon Therapeutics is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. At a time when Talon could not access capital from the public markets, Deerfield provided a $30 million facility which became available based on clinical milestones. In June 2010, Talon completed a deal that involved Deerfield participating for up to $10 million of a potential $100 million deal that was led by Warburg Pincus.